Anti-angiogenic effects of SR 25989 in cancer
Author Information
Author(s): Mah-Becherel M C M, Céraline J, Deplanque G, Chenard M-P, Bergerat J-P, Cazenave J-P, Klein-Soyer C
Primary Institution: Institut de Recherche contre les Cancers de l'Appareil Digestif, Hôpitaux Universitaires de Strasbourg
Hypothesis
Does the thienopyridine SR 25989 inhibit angiogenesis and metastasis in a murine model?
Conclusion
SR 25989 significantly reduces the number and size of lung metastases without affecting primary tumor growth.
Supporting Evidence
- SR 25989 inhibited spontaneous microvessel formation in vitro.
- Treatment with SR 25989 reduced the number of lung metastases by 33%.
- Metastases in treated mice showed no neovascularization.
- Primary tumor growth was not significantly affected by SR 25989.
Takeaway
A drug called SR 25989 helps stop cancer from spreading by blocking the growth of new blood vessels that tumors need to grow.
Methodology
The study used in vitro assays to measure angiogenesis and an in vivo murine model to assess the effects of SR 25989 on tumor growth and metastasis.
Limitations
The study did not fully analyze the effects of SR 25989 on primary tumor growth due to ethical considerations regarding animal welfare.
Participant Demographics
Male Wistar rats and male C57BL/6 mice were used in the experiments.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website